Form 10-Q Harmony Biosciences Hold For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James
April 30, 2024 12:17 PM EDTRaymond James analyst Danielle Brill raised the price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) to $37.00 (from $34.00) while maintaining a Outperform rating.
The analyst comments "Wakix 1Q sales of $154.6M (-8.2% q/q) slightly beat our $152.9M estimate (vs consensus $154.7M), and FY24 revenue guidance of... More
